Cupid Limited Reports Q3 FY26 Business Update and Expansion Plans
Filing Summary
Cupid Limited has released its Q3 FY26 business update, highlighting strong operational momentum and global expansion initiatives. The company reports its highest-ever order book and anticipates exceeding its FY26 revenue guidance of ₹335 crore and PAT of ₹100 crore. Cupid is progressing with its capacity expansion at the Palava facility and plans to establish an FMCG manufacturing unit in Saudi Arabia by March 2027. The company continues to expand its FMCG portfolio and maintains a significant presence in international markets, exporting to over 110 countries.
Cupid Limited has issued a business update for Q3 FY26, detailing its operational progress and strategic initiatives. The company reports strong demand visibility and execution, contributing to its highest-ever order book. Cupid anticipates surpassing its FY26 revenue guidance of ₹335 crore and PAT of ₹100 crore, supported by stable demand and operational efficiencies.
The company is advancing its capacity expansion at the Palava, Maharashtra facility, which aligns with its broader growth strategy. This expansion is expected to increase production capacity by approximately 770 million male condoms and 75 million female condoms annually. Cupid’s FMCG business is gaining traction in India, with products like Petroleum Jelly, Face Wash, and Talcum Powder receiving positive consumer feedback.
Cupid is focusing on strengthening its presence in the GCC region, with plans to establish an FMCG manufacturing facility in Saudi Arabia. This facility aims to enhance supply responsiveness and market proximity, with completion targeted for March 2027, subject to regulatory approvals. The Saudi FMCG market presents opportunities due to factors like population growth and rising consumer spending.
The company holds key international certifications for its product portfolio, including male and female condoms, lubricants, and IVD kits. Recent CE certifications and the anticipated WHO prequalification for certain products are expected to support growth in international markets. Cupid’s investment in GII Healthcare Investment Limited Fund has appreciated to approximately 1.2 times the initial investment made in October 2025.
The timeline for Cupid’s strategic initiatives includes ongoing work at the Palava facility and the planned completion of the Saudi FMCG manufacturing unit by March 2027. The company continues to assess opportunities in the FMCG sector while maintaining a disciplined approach to capital allocation.
Cupid Limited, established in 1993, is a leading manufacturer of male and female condoms, water-based personal lubricants, and IVD kits. The company has expanded its product offerings to include FMCG products such as deodorants, perfumes, and personal care items. Cupid exports to over 110 countries and has a long-term agreement with WHO/UNFPA, reflecting its commitment to public health and ethical business practices.